Isabelle Aerts

4.9k total citations · 1 hit paper
125 papers, 2.6k citations indexed

About

Isabelle Aerts is a scholar working on Ophthalmology, Oncology and Molecular Biology. According to data from OpenAlex, Isabelle Aerts has authored 125 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Ophthalmology, 39 papers in Oncology and 37 papers in Molecular Biology. Recurrent topics in Isabelle Aerts's work include Ocular Oncology and Treatments (46 papers), Neuroblastoma Research and Treatments (32 papers) and Glioma Diagnosis and Treatment (29 papers). Isabelle Aerts is often cited by papers focused on Ocular Oncology and Treatments (46 papers), Neuroblastoma Research and Treatments (32 papers) and Glioma Diagnosis and Treatment (29 papers). Isabelle Aerts collaborates with scholars based in France, United Kingdom and United States. Isabelle Aerts's co-authors include François Doz, Livia Lumbroso‐Le Rouic, Laurence Desjardins, Birgit Geoerger, Hervé J. Brisse, Marion Gauthier‐Villars, Darren Hargrave, Éric Bouffet, Alexia Savignoni and Mark W. Russo and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Isabelle Aerts

118 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations

2023 125 citations Éric Bouffet, Jordan R. Hansford et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isabelle Aerts France	28	839	795	761	695	646	125	2.6k
Marion Gauthier‐Villars France	25	1.0k 1.2×	526 0.7×	838 1.1×	145 0.2×	284 0.4×	67	2.3k
Michael N. Needle United States	31	1.0k 1.2×	396 0.5×	2.5k 3.3×	1.1k 1.6×	1.9k 2.9×	72	5.3k
P N Plowman United Kingdom	28	482 0.6×	433 0.5×	726 1.0×	396 0.6×	773 1.2×	94	2.8k
Torsten Pietsch Germany	31	1.3k 1.5×	114 0.1×	466 0.6×	1.5k 2.1×	731 1.1×	78	3.4k
Regina I. Jakacki United States	35	969 1.2×	158 0.2×	679 0.9×	2.3k 3.3×	756 1.2×	94	4.0k
John L. Hungerford United Kingdom	34	787 0.9×	2.8k 3.5×	1.3k 1.7×	328 0.5×	431 0.7×	121	3.7k
David W. Kimmel United States	31	1.2k 1.4×	161 0.2×	639 0.8×	1.9k 2.8×	873 1.4×	50	3.8k
Dan S. Gombos United States	22	457 0.5×	1.2k 1.5×	624 0.8×	164 0.2×	414 0.6×	87	1.9k
Tianni Zhou United States	26	835 1.0×	100 0.1×	222 0.3×	1.8k 2.6×	567 0.9×	34	2.4k
Masao Matsutani Japan	34	789 0.9×	107 0.1×	655 0.9×	2.0k 2.9×	683 1.1×	98	3.5k

Countries citing papers authored by Isabelle Aerts

Since Specialization

Citations

This map shows the geographic impact of Isabelle Aerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Aerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Aerts more than expected).

Fields of papers citing papers by Isabelle Aerts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Aerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Aerts. The network helps show where Isabelle Aerts may publish in the future.

Co-authorship network of co-authors of Isabelle Aerts

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Aerts. A scholar is included among the top collaborators of Isabelle Aerts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Aerts. Isabelle Aerts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dufresne, Armelle, Mehdi Brahmi, Claire Cropet, et al.. (2024). 59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts. ESMO Open. 9. 102449–102449.

Moreno, Lucas, Pierre Teira, James M. Croop, et al.. (2023). A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Frontiers in Pediatrics. 11. 1183295–1183295. 5 indexed citations

Wolkenstein, P., et al.. (2023). French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study. European Journal of Medical Genetics. 66(5). 104734–104734. 1 indexed citations

Lacour, Brigitte, Perrine de Crouy-Chanel, Isabelle Aerts, et al.. (2023). Residential proximity to vines and risk of childhood embryonal tumours in France - GEOCAP case-control study, 2006–2013. Environmental Research. 240(Pt 2). 117417–117417. 1 indexed citations

Geoerger, Birgit, Lynley V. Marshall, Karsten Nysom, et al.. (2023). Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer. 188. 8–19. 3 indexed citations

Bouffet, Éric, Jordan R. Hansford, Maria Luisa Garrè, et al.. (2023). Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. New England Journal of Medicine. 389(12). 1108–1120. 125 indexed citations breakdown →

Trippett, Tanya, Helen Toledano, Quentin Campbell Hewson, et al.. (2022). Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study. Targeted Oncology. 17(3). 283–293. 30 indexed citations

Pasqualini, Claudia, Lydie Cassard, Nicolás André, et al.. (2021). Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer. 150. 53–62. 36 indexed citations

Rouic, Livia Lumbroso‐Le, Raphaël Blanc, Alexia Savignoni, et al.. (2021). Selective Ophthalmic Artery Chemotherapy with Melphalan in the Management of Unilateral Retinoblastoma: A Prospective Study. Ophthalmology Retina. 5(8). e30–e37. 5 indexed citations

10.

Michon, Jean, Hélène Pacquement, Isabelle Aerts, et al.. (2019). Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatric Blood & Cancer. 66(6). e27641–e27641. 23 indexed citations

11.

Kieran, Mark W., Birgit Geoerger, Ira J. Dunkel, et al.. (2019). A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors. Clinical Cancer Research. 25(24). 7294–7302. 58 indexed citations

12.

Aerts, Isabelle, Daniel Orbach, Irène Jiménez, et al.. (2018). Enrollment in early‐phase clinical trials in pediatric oncology: The experience at Institut Curie. Pediatric Blood & Cancer. 65(5). e26916–e26916. 6 indexed citations

13.

Millot, Gaël A., Constance Wells, Hervé J. Brisse, et al.. (2018). Correlation between RB1germline mutations and second primary malignancies in hereditary retinoblastoma patients treated with external beam radiotherapy. European Journal of Medical Genetics. 62(3). 217–223. 23 indexed citations

14.

Eloy, Philippine, Catherine Dehainault, Meriem Sefta, et al.. (2016). A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1. PLoS Genetics. 12(2). e1005888–e1005888. 26 indexed citations

15.

Cassoux, Nathalie, Isabelle Aerts, Livia Lumbroso‐Le Rouic, Paul Fréneaux, & Laurence Desjardins. (2016). Eye Salvage with Combination of Intravitreal and Intracameral Melphalan Injection for Recurrent Retinoblastoma with Anterior Chamber Involvement: Report of a Case. Ocular Oncology and Pathology. 3(2). 129–132. 11 indexed citations

16.

Castéra, Laurent, Catherine Dehainault, Dorothée Michaux, et al.. (2012). Fine mapping of whole RB1 gene deletions in retinoblastoma patients confirms PCDH8 as a candidate gene for psychomotor delay. European Journal of Human Genetics. 21(4). 460–464. 9 indexed citations

17.

Geoerger, Birgit, Isabelle Aerts, María José Casanova, et al.. (2012). UPDATED RESULTS FROM A PHASE I STUDY OF LDE225, A SMOOTHENED ANTAGONIST, IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA OR OTHER SOLID TUMORS. UCL Discovery (University College London). 4 indexed citations

18.

Juergens, Heribert, Najat C. Daw, Birgit Geoerger, et al.. (2011). Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. Journal of Clinical Oncology. 29(34). 4534–4540. 165 indexed citations

19.

Rubie, Hervé, Birgit Geoerger, Didier Frappaz, et al.. (2010). Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European Journal of Cancer. 46(15). 2763–2770. 15 indexed citations

20.

Petit, Arnaud, Isabelle Aerts, Hélène Pacquement, et al.. (2009). Fin de vie en oncologie pédiatrique : une période active de traitement. MTP. Médecine thérapeutique pédiatrie. 12(3). 127–133. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact